Current Research Studies

A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection

RS_GS_US_320_1092

Phase: II/III
Clinicaltrials.gov ID: NCT02932150

What is the goal of the study?

Randomized (2:1), double-blind, placebo-controlled, two-part, multicenter (Approximately 40 centers in North America, Europe, and Asia), study of the pharmacokinetics, safety, tolerability, and antiviral activity of the TAF 25 mg tablet administered once daily for 24 weeks in treatment-naïve and treatment-experienced adolescent subjects with CHB. A total of 75 adolescents (12 to < 18 years of age) will be enrolled to receive the TAF 25 mg tablet or matching placebo once daily.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Evelyn Hsu
Study Team Member: Mason Nuding, [email protected]